相关实验视频

Updated: Jul 9, 2025

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

miR-877-5p作为三阴性乳腺癌发展和代谢综合征之间的潜在联系

Juana Moro¹, Agustina Grinpelc¹, Paula Lucía Farré¹

¹Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires 1428, Argentina.

International journal of molecular sciences

|December 9, 2023

概括

代谢综合征增加了乳腺癌的风险和攻击性. 研究人员将miR-877-5p确定为与代谢综合征和三阴性乳腺癌相关的循环microRNA,这表明它是潜在的治疗标.

科学领域:

生物化学生物化学
分子生物学分子生物学
在瘤学瘤学.

背景情况:

代谢综合征 (MS) 是已知的乳腺癌 (BC) 的风险因素,特别是像三阴性乳腺癌 (TNBC) 这样的侵袭性亚型.
仍然不完全理解MS和BC进展之间的分子联系.
微RNAs (miRNAs) 是基因表达的关键调节者,涉及各种疾病,包括癌症.

研究的目的:

在患有与代谢综合征 (AAMS) 相关的改变,也影响乳腺癌的患者中识别循环的miRNA.
研究特定miRNAs,如miR-877-5p在TNBC进展和存活中的作用.

主要方法:

来自AAMS妇女的血微阵列分析以检测改变的miRNAs.
在患者血和瘤组织中对特定miRNAs (let-7b-5p,miR-28-3p,miR-877-5p) 的定量分析.
对公开数据库的生物信息分析,以检测BC的miRNA表达.
对miR-877-5p的目标基因 (IGF2,TIMP3) 的验证.
在体外研究使用miRNA抑制剂在TNBC细胞模型 (4T1) 中.

主要成果:

在患有AAMS的妇女的血中发现了23个循环miRNA,调节与癌症相关的过程.
在AAMS患者和BC瘤患者的血中,miR-877-5p显著增加,与生存率较差相关.
在基底类TNBC亚型中,miR-877-5p的表达最高.
IGF2和TIMP3被验证为miR-877-5p的基因,在BC组织中表达减少.
在TNBC模型中,抑制miR-877-5p降低了活力和瘤生长.

结论:

循环中的miR-877-5p是代谢综合征相关乳腺癌的潜在生物标志物.
miR-877-5p在TNBC进展中发挥作用,可能代表治疗标.
抑制miR-877-5p证明了TNBC治疗的治疗潜力.

关键词:

乳腺癌乳腺癌乳腺癌代谢综合征代谢综合征这就是miRNAs.

更多相关视频

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Published on: November 5, 2021

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...